To separate liver and bone alkaline phosphatase (ALP) isoenzymes in human serum, we used high-performance affinity chromatography (HPAC) on a column of wheat-germ lectin conjugated to 7-sm-diameter silica particles and an eluent containing N-acetyl-D-giucosamine (NAG). On-line spectrophotometric detection of ALP involved pumping diethanolamine-buffered p-nitrophenyl phosphate solution postcolumn. Bone and liver isoenzymes could be separated into two peaks with only 10% overlap when an exponential gradient was used. A linear-step gradient separated 80.9% of liver ALP and 91.6% of bone ALP in two distinct peaks. True bone and liver ALP peak areas for the linear-step gradient were determined by using correction factors, because each peak contained a co-eluted portion of the other ALP isoenzyme. The detection limit improved 10-fold over those of other techniques for ALP isoenzymes, owing to the relatively large sample that could be applied to the column. Correlation with a urea-inactivation procedure was reasonable for patients' serum samples (r = 0.98 and 0.79 for liver ALP and bone ALP, respectively). inactivation analysis has such a poor limit of detection that determination of ALP isoenzymes by heat inactivation requires the sample to have more than twice the upper limit of normal total ALP activity (4). This limitation diminishes the utility of the test for physicians who request evaluation of ALP isoenzymes in samples with normal total ALP activity, to help decide difficult cases. In one study of 600 samples with normal total ALP activity, 5% had above-normal activity of one of the ALP isoenzymes, with malignant disease confirmed in 72% of these 5% (1). In our experience at the Mayo Clinic, 30% of the ALP isoenzyme requests involve samples for which the total ALP is within the normal reference interval (e.g., 352 of 1273 samples, representing requests during two months).
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(3).
This extremely labor-intensive approach requires strict control of conditions if results are to be accurate (1). Furthermore, inactivation analysis has such a poor limit of detection that determination of ALP isoenzymes by heat inactivation requires the sample to have more than twice the upper limit of normal total ALP activity (4). This limitation diminishes the utility of the test for physicians who request evaluation of ALP isoenzymes in samples with normal total ALP activity, to help decide difficult cases. In one study of 600 samples with normal total ALP activity, 5% had above-normal activity of one of the ALP isoenzymes, with malignant disease confirmed in 72% of these 5% (1). In our experience at the Mayo Clinic, 30% of the ALP isoenzyme requests involve samples for which the total ALP is within the normal reference interval (e.g., 352 of 1273 samples, representing requests during two months).
A successful analytical strategy must include recognition of the subtle structural differences between the isoenzymes.
Because both human liver and bone ALP apparently are derived from the same gene locus (5) (6) (7) , any structural differences must result from differences in post-translational modifications of the respective isoenzymes or in the accompanying proteins or lipids that invariably co-dissociate from the cellular source.
The exact nature of the structural difference between bone and liver ALP has not been fully elucidated. Sialic (neuraminic) acid differences are implied from experiments that demonstrate equal electrophoretic mobilityfor bone and liver ALP after complete treatment with sialidase (EC 3.2.1.18) (5, 8). There are, however, other differences between bone and liver ALP isoenzymes that lead to different physicochemical properties not accounted for by a difference in sialic acid groups (9) .
A difference inthe arrangement and (or) concentration of sugar groups specific for wheat-germ lectin (WGL) is indicated for the two isoenzymes by precipitation (10, 11), affinity electrophoresis (10, 12, 13), and affinity chromatographic (14, 15) studies involving WGL. Recently we reported that the bone and liver ALP isoenzymes are incompletely resolved by low-performance WGL affinity chromatography (15) . Expanding upon this work, we report here the first use of high-performance affinity chromatography (HPAC) in the separation of bone and liver ALP isoenzymes with use of WGL coijugated to diol-bonded silica. A post-column HPLC setup is used, including a continuous on-line enzyme detection scheme (16, 17) with a modification in the post-column reactor (18). Mobile-phase gradients are pumped through the column by a two-pump gradient system. Substrate solution is pumped into the column effluent with a third pump. A zero-dead-volume mixing tee is used to mix the two lines. The substrate/ effluent mixture is pumped through a reactor to a flowthrough spectrophotometer.
The Samples. Human bone ALP and liver ALP controls were prepared by pooling patients' sera that had above-normal total ALP activity, >90% of it being either the bone or liver isoenzyme. We diluted the pooled sera to an activity of -250 UIL, using an aqueous solution containing 50 g of bovine albumin (New England Reagent Laboratory, East Providence, RI) and 9 g of NaC1 per liter, and stored the controls in 0.5-mL aliquots at -78 #{176}C. The ALP isoenzyme values for the thawed bone and liver controls, as determined by a procedure involving inactivation with urea (19), were (a) bone 237, liver 24, and intestinal 0 U/L, and (b) 19, 218, and 0 U/L, respectively. Patients' serum samples were used in the correlation studies comparing the chromatographic technique with the urea-inactivation procedure. All serum samples (control and patient) were filtered through low-protein-binding syringe filters (Acrodiscs; Gelman Sciences, Ann Arbor, MI) before chromatography. For all studies we used a single injection of the sample, except for the recovery study, in which we made triplicate runs. To adjust the pH of the application and elution buffers, we used NaOH. To adjust the pH of the post-column substrate solution, we used HC1. All mobile phases were ifitered through 0.22-/1m (pore size) filter paper except the post-column substrate solution.
Apparatus
The HPLC system consisted of chromatographic and Post-column components included an LC-6A pump, an SPD-6AV UV/VIS detector, and a C-MA data processor (all from Shimadzu), a Lee visco jet micro-mixer used as a mixing tee ( Protein assay of WGL silica. The amount of protein conjugated to the diol-bonded silica was determined with a BCA protein assay kit (Pierce Chemical Co., Rockford, IL). The room-temperature protocol as given in the kit instructions was followed, with the following changes: diol-bonded silica was assayed for a blank reading, and this absorbance was subtracted from all the WGL silica samples' absorbances; all samples and standards were sonicated under reduced pressure (20 in. Hg) for 5 min; the contents of all the test tubes were vortex-mixed several times during the incubation step; the supernate was removed from the silica by centrifugation pouring off; and WGL was used for the standard curve. Using this procedure, we found that 29.3 mg of WGL was conjugated per gram of diol-bonded silica.
Column-packing procedures.
The WGL silica was suspended in about 50 mL of phosphate buffer (0.1 moIJL, pH 7) and sonicated for 30 s to break up any silica agglomerates. The silica solution was then filtered through a 45-jnn sieve (cat. no. 04-881-5EE; Fisher). The silica was then allowed to settle, and the supernatant fluid was poured off to remove the fines. The silica was resuspended in about 50 mL of the phosphate buffer. The inlet endfitting of the empty column was removed; the outlet endfitting (with fit) was fitted tightly to the column. The column was clamped vertically, with the inlet end up, and a vacuum line (20 in. Hg) was attached to the outlet end via a filtering flask trap. A small piece of Tygon tubing was attached to the inlet end to act as a reservoir basin. The silica suspension was added with a Pasteur pipette. The silica suspension was added until the column was packed above the column top. After disconnecting the column, excess silica was scraped off the top with a spatula and the inlet fitting, with a fit, was attached.
The saturator columns were packed by dry-ifil packing (20) .
Chromatographic conditions. The WGL column was at ambient temperature.
The post-column reactorwas immersed in a water bath at 30.0 #{176}C. The post-column substrate solution was placed in an ice bath. The two column pumps were used to establish linear, exponential, or step gradients as described below. Flow-rates were 1 mL/min for the mobile phase through the WGL column and 1 mL/min for the post-column substrate solution, which was kept on ice. The wavelength of detection was 405 nm. The volume of sample injected ranged from 50 tL to 200 L, depending on the experiment. Measured system volumes were 3.78 mL from the switching valve of the elution buffer pump to the mixing chamber, 6.17 mL from the entrance of the mixing chamber to the detector flow cell, and 3.11 mL from the mixing tee to the detector flow cell. The mixing chamber had a volume of 1.15 mL (according to the manufacturer). The time for a programmed solvent change to reach the detector, with column effluent and post-column substrate solution flow-rates of 1 mL/min, was 4.69 mm.
Both exponential NAG gradients (E gradients) and gradients with linear and step changes in NAG (LS gradients) were used, as given by equations 1-7 in Table 1 . It should be noted that equations 1-7 resulted from system dead volumes, in addition to the programmed changes in the gradient. Thus, equations 1-7 give the actual concentrations of NAG at the detector at time t.
Bound NAG was washed from the column (i.e., between runs) by pumping application buffer through the column for at least 5 mm at 1 mL/min. This was sufficient washing time, as determined by an experiment in which we found that the retention time of 4-methylumbelliferyl-N-acetylf3-D-glucosaminide after a 5-mm washing time was the same as that after a 1-h washing time (detected as absorbance at 318 nm).
Other procedures. Analytical recovery of ALP activity for both liver and bone ALP was determined by measuring peak areas for ALP controls injected onto the WGL column and comparing them with peak areas for a blank study in which ALP controls were injected onto HPLC tubing (total blank). The peak areas for the blank study needed correction as described below, because the controls had components absorbing at 405 nm that were not related to ALP activity. The amount of peak area in the blank study resulting solely from ALP activity in the ALP control (ALP blank) was determined by measuring the peak area due to non-ALP components in the controls (non-ALP blank) and subtracting this from the peak area of the total blank. The peak area for the non-ALP blank was determined from chromatograms of ALP controls injected onto HPLC tubing, with a pseudo-substrate solution (substrate solution devoid of substrate) pumping post-column. For these experiments, 100 j.tL of bone and liver ALP controls were injected in triplicate.
The mobile phase for the column recovery studies consisted of an LS gradient, and for the tubing recovery studies it consisted of application buffer.
Linearitywas determined by injection of a series of ALP standards, prepared from aliquots of ALP controls diluted with 0.2 mol/L NaC1 (exceptfor the highest standard, which was an undiluted ALP control). ALP standards were injected onto the WGL column and blank HPLC tubing. A LS gradient was used for the column study, while application buffer was used for the tubing study. For the column study, bone and liver ALP standards were injected. Liver ALP standards were injected for the tubing study. Peak heights for the tubing studies were corrected for non-ALP components by subtracting peak heights for the corresponding non-ALP blank (described above). Injection volumes were 200 jL.
To heat-inactivate bone and liver controls we used a published procedure (21). Freshly thawed ALP controls were heated for 10 mm in a water bath set at 56.0 #{176}C.
Concurrently,a set of freshlythawed ALP controls was kept at room temperature for 10 mm. The heated and (2) non-heated controls were then submerged in ice water for 5 mm. Chromatography, after sample filtration, was done
immediately, 200-L samples being injected. (5) Chromatography with E Gradients (6) Figure 1 shows superimposed chromatograms of human Table 1 , equation2) Peak 1 is the non-retained components, peak2 is liver ALP, and peak3 is bone ALP (with peak numbers increasing from shortest to longest retention time). Chromatographicconditions as in Materialsarid Methods tively. Separation of the liver and bone peaks is seen to improve in Figure 1 with decreased slope of the B gradient-consistent with results predicted by theory for linear gradients (22). The best separation is seen in Figure 1C , in which there is only a 10% overlap of the liver with the bone ALP peak (compared to 58% and 45% for the peaks in Figure l#{192} and lB. respectively). The disadvantage of using the B gradient of Figure 1C is that the quantification of the bone ALP peak area is subject to inaccuracybecause of the large peak width, which presumably is the result of the intra-tissue heterogeneity of human ALP isoenzymes (1, 14, [23] [24] [25] [26] [27] . However, an important conclusion from this study is that the liver and bone isoen.zymes of ALP are distinct populations of heterogeneous glycoprotemns, which require a shallow gradient of NAG for "complete" separation on a WGL column.
Results and Discussion

Chromatography with LS Gradient
ALP controls. An LS gradient consisting of a shallow linear gradient of NAG followed by a step change to high concentration NAG (Table 1 , equations 4-7) was developed in an attempt to improve the quantification of the bone ALP, as well as to shorten analysis time. Chromatograms of human bone and liver ALP controls at LS gradient conditionsare given in Figure 2 . The liver ALP control resolved into two distinct peaks (Figure 2A ): a low-affinity faction eluting during the linear gradient (peak L2, 77% of the injected ALP activity) and a high-affinity fraction eluting at the step change (peak L3, 23% of the injected TIme,mm 
ALP activity).
The bone ALP control resolved into three distinct peaks ( Figure 2B ): two low-affinity fractions eluting during the linear gradient (peaks B2a and B2b, 19% of the injected ALP activity) and a high-affinity faction eluting at the step change (peak B3, 81% of the injected ALP activity). Peak B2a had the same retention time as L2 and was presumed to be liver ALP. As in the E gradient, the first peak (Bi and Li) was attributed to non-retained components and had no ALP activity.
Linearity.
The range of linearity
for chromatographic analysis is usually determined from experiments in which standards of increasing concentration of analyte are assayed. In this work, we did not have ALP standards of sufficiently high concentration to adequately determine the range of linearity.
However, a minimum upper limit to linearity was assessed as described below. There are three factors to consider in assessing the linearity of an HPLC technique utilizing a post-column substrate detection scheme: the capacity of the column for the analyte, the linearity of the detector, and the substrate depletion in the effluent line.
The first factor is the capacity of the WGL colunm for ALP. From the values of the molecular mass of WGL [23 500 Da (28)], the packing density of the WGL silica (assumed to be 0.5 g/mL), the WGL coverage on the diol-silica, and the column dimensions, the total WGL content of the column was calculated to be 0.52 mol. The amount of ALP injected onto the WGL column in a 200-FL sample of liver ALP control was calculated to be 2.7 x iO j.zmol, using values of 135 000 Da for the molecular mass (29) and 1300 kU/g for the activity For this reason, a strategy of conjugating the maximum amount of WGL to the silica was taken in the synthesis of the packing material. All things considered, there was no evidence in the present work that the capacity limits were reached for the WGL column, and so capacity is not likely to be a limiting factor for linearity. The second and third factors, detector linearity and substrate depletion, are important determinants of linearity in this work. We examined the deviation from linearity resulting from these two effects by injecting ALP standards onto blank tubing. These results ( Figure 3) were then extrapolated to determine the linearity for samples injected onto a column. Figure 3 shows no deviation from linearity for ALP standards injected onto blank tubing up to at least 237 UIL. For the WGL column, linearity to higher ALP concentrations is expected, because the sample is diluted as it traverses the column. To determine the concentration of ALP injected on the WGL column that would give an equal peak height as that for a 237 U/L standard injected onto blank tubing, we did a calibration study on the column in which 0-237 UIL standards were injected and the result was extrapolated.
From this data analysis, linearity for the WGL column with use of an LS gradient was predicted up to 5190 Ti/L for liver ALP and 1640 U/b for bone ALP.
Limit of detection. We determined the lower limit of detection from the standard error of they-estimate (s,,) of the least-squares regression line for ALP standards injected onto the WGL column (Figure 4 ), using a 3 s>,,3, criterion (30). The limit of detection was found to be 15 and 12 U/b for liver ALP and bone ALP, respectively.
This represents approximately a 10-fold improvement in detection limit over existing techniques and allows for determinations of ALP isoenzymes to the lower limit of the normal reference interval.
Analytical recovery. Recovery experiments for ALP activity injected on the WGL column are described in Materials and Methods. In general, recovery was determined by comparing peak areasforinjections made on blank tubing with peak areas obtained from chromatographic runs. This is valid as long as the experiments were performed within the range of linearity.
This was shown to be the case, as discussed previously. Recovery was excellent: 99% for liver ALP and 94% for the bone ALP. Comparison of the Li and Bi peak areas with the corresponding non-ALP blank peak areas showed Li and Bi to be less, indicating no ALP activity was present in the non-retained peaks (Li and Bi).
Heat-stability studies. In the chromatography of ALP controls with use of an LS gradient, most of the ALP activity in the liver control (77%) was eluted in peak L2, while most of the ALP activity in the bone control (81%) was eluted in peak B3 (Figure 2 ). Peaks L2 and B3 will subsequentlybe referredto as the major liver ALP and major bone ALP peaks, respectively. The ALP fraction of the control not eluting in the major peak will be called the minor peak, and it had a retention time similar to that of the other isoenzyme's major peak. Whether the minor peak resulted from heterogeneity of the isoenzyme, or from contamination of the control material by the other ALP isoenzyme, or a combination of both, required further investigation. As noted previously, however, results from the E gradient study suggest only a small amount of isoenzyme contamination.
To answer this question quantitatively, heat-stability studies were performed as described in Materials and Methods. In general, ALP controls were heated at 56#{176}C for 10 mm and were compared with ALP controls that were not heated,with respect to peak areas obtained for samples injected onto the WGL column. Analysis of data from a previously published study (4) revealed an average remaining ALP activity of 35.5% (SD 8.6%) after similar heat treatment for 66 sera containing only liver ALP and 11.9% (SD 5.6%) for 76 sera containing only bone ALP. This informationcould be used to determine the isoenzyme composition of the minor peaks by comparing the peak area of the minor peak for a heated control with that of a non-heated control. Thus, ifthe peak area of the minor peak for the heated liver control decreased to 30-40% of the value for the non-heated control, one could reasonably conclude that this fraction was totally liver; whereas if the peak area decreased to 5-i5%, the fraction was totally bone. Any percentage between these values would indicate a mixture of bone and liver isoenzyme in the minor peak fraction. In this case, the percentage of each isoenzyme in the minor peak could be determined from the value of the peak area remaining after heating. The above conclusions are based on the assumption that all fractions of a particular ALP isoenzyme have the same characteristics of heat stability. The following results were obtained from the heat-stability studies. For the heated liver control, the area of the major peak (peak L2) was 51.7% of that of the non-heated control and the area of the minor peak (peak L3) was 43.4% of that of the non-heated control. For the heated bone controls, the decrease was to 12.0% for the major peak (peak B3) and to 35.9% for the minor peak (peaks B2a and B2b combined). From these results, the liver control was determined to be 94.8% liver isoenzyme, with the percentage of ALP activity due to liver isoenzyme in the major and minor peak being 99.4% and 79.3%, respectively. The bone control was determined to be 85.9% bone isoenzyme, with the percentage of ALP activity due to bone isoenzyme in the major and minor peak being 96.7% and 38.9%, respectively.
The above numbers give the percentages of isoenzyme within a peak. These percentages will change depending on the relative amounts of isoenzymes in the sample. Of more fundamental concern was the distribution of the isoenzymes between the peaks, because this quantity should be constant regardless of isoenzyme concentration.
From the above data, we determined that 80.9% of liver ALP was eluted in peak 2 (L2 or B2) and 91.6% of bone ALP was eluted in peak 3 (B3 or L3), with the remaining liver and bone ALP being eluted in peaks 3 and 2, respectively.
Studies of Patients with Use of an LS Gradient
Although 80-90% of bone and liver ALP was eluted in distinct peaks, factors correcting peak areas were needed for accurate quantification of the isoenzymes.
The true peak area due to bone isoenzyme (B) and liver isoenzyme (L) are given in equations 8 and 9, where P2 and P3 are the peak areas of peaks 2 and 3, respectively. These equations were derived by using the results for the distribution of isoenzymes between peaks 2 and 3, obtained in the heatstability studies.
) Eight patients' sera high in liver ALP and nine patients' sera high in bone ALP were chromatographed on the WGL column with use of an LS gradient. Corrected peak areas were compared with isoenzyme activities determined by a urea-inactivation procedure.
The normal reference intervals for the urea-inactivation procedure were as follows: 90-239 U/b for total ALP (males >18 y), 20-130 U/b for liver ALP, and 20-120 U/b for bone ALP. The results are given in Figure 5 , in which the corrected peak area for the chromatographic method is plotted vs the ALP isoenzyme activity, as determined by the urea-inactivation method. Figure 5A gives the results for the liver isoenzyme and Figure 5B gives the results for the bone isoenzyme. All samples were plotted; however, only samples predominant in the particular isoenzyme that was plotted were used in the determination of the least-squares regression line, because the lower limit of detection for the urea technique precluded its use for samples in which the concentration of the isoenzyme was not high. Uver ALP conc (U/L) x iO graphic technique at low isoenzyme concentrations, because there was no comparable methodology. From the detection-limit studies previously discussed, the technique was applicable to the 10-20 U/b range. This conclusion, however, was only demonstrated for the quantification of the predominant ALP isoenzyme.
In Figure 5A , the data points at low liver ALP concentrations were from samples having increased bone ALP. These data points show a positive bias in relation to the regression line. In contrast, samples low in bone ALP but high in liver ALP do not show a bias but do show a large amount of scattering about the bone ALP regression line ( Figure 5B ). In this case, negative peak areas were calculated for four of the samples. This occurred because the peak area for peak 3 was proportionately too small in comparison with the peak area of peak 2. As determined by the previously mentioned method, peak 3 must be at least 19.1% of the total ALP peak area. However, values for peak 3 for the samples giving negative peak areas were less than this, being 12.4%, 12.9%, 14.5%, and 18.0%.
The positive bias noted in Figure 5A for the low liver-ALP samples could result from discrepancies in either the chromatographic technique or the urea-inactivation technique, and thus offered little insight into the performance of the chromatographic technique for determining the minor isoenzyme component. More telling, however, were the low bone ALP results in Figure 5B . The negative peak areas were indicative of a problem. It is doubtful that the negative peak areas resulted from an inaccurate determination of equation 8, because a substantial change in the parameters (35%) is required to yield a positive peak area. A more likely explanation is that the distribution of the bone isoenzymes between peaks 2 and 3 was different for some of the patients' samples. This difference in distribution could reflect a change in the glycosylation pattern of the ALP resulting from certain disease states. Work done by Koyama et al. (31) supports this contention, showing a difference in sugar composition between normal and tumorassociated liver ALP. This issue needs to be explored further.
Conclusions
The most pertinent role of ALP isoenzyme analysis is as a quick screen for cholestasis and secondarily, after determining that ALP is increased, to determine the tissue source. The most important sources are liver and bone. This represents the reasoning for most of a clinical laboratory's requests, because the disease process leading to an increase in ALP usually leads to a preferential increase in one of the isoenzymes. Good correlation in the quantification of the predominant isoenzyme by the HPAC method in comparison with the urea-inactivation method has been shown in the present work. Furthermore, the HPAC method has the distinct advantage of being able to determine the concentration of the predominant isoenzyme in a sample having a normal concentration of total ALP.
An additional requirement in ALP isoenzyme methodology that has yet to be realized is the determination of the minor ALP isoenzyme component against a background of increased amounts of the other ALP isoenzyme. This is important for the detection of an increase in an ALP ieoenzyine for individuals that have a physiological increase in ALP (due to bone growth, increased age, pregnancy, etc.) and for monitoring the spread of malignancies to liver and bone (1). At present, there are limitations in the HPAC technique in quantifying the minor ALP isoenzyme, probably stemming from a difference in the distribution of the isoenzymes between the two ALP peaks for different samples. This will affect the values of the parameters in equations 8 and 9. Further characterization of the HPAC technique is needed before the concentration of the minor ALP isoenzyme can be accurately determined.
